IVRA
Growthmelphalan hcl
NDAINTRAVENOUSSOLUTION
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
IVRA (melphalan hcl) is type. First approved in 2023.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IVRA (melphalan HCl) is an intravenous bifunctional alkylating agent approved in August 2023 that works by forming interstrand cross-links with DNA to induce cytotoxicity in tumor cells. It is active against both resting and rapidly dividing malignant cells, making it suitable for hematologic and solid tumor applications. The specific indication(s) for this formulation are not detailed in available data.
Growth10.0 years to LOE
As a recently approved oncology product in growth phase, the brand team is likely expanding to build market presence with moderate-sized commercial and medical affairs functions.
Mechanism of Action
type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
Started Jul 2020
67 enrolled
Multiple Myeloma
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Started Jan 2010
24 enrolled
Multiple Myeloma
Career Relevance
Working on IVRA offers exposure to oncology commercialization during the critical growth phase of a newly approved IV chemotherapy. Limited current job openings suggest a lean team structure, but the 10-year patent window and small-molecule modality create opportunities for long-term career stability in a specialty oncology setting.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.